External Advisory Committee

Currently comprised of 17 advisors, Moffitt’s External Advisory Committee (EAC) meets annually, typically in the spring, and provides key advice to Moffitt leadership on all areas of cancer research including: strategic planning, Program Aims and progress, transdisciplinary activities, research in the catchment area, Shared Resources, Centers of Excellence, training and education, infrastructure, facilities, administration and clinical research activities. Moffitt’s EAC is composed of experts in their respective areas of cancer research and leadership and are matched to Moffitt research areas. EAC members serve a three-year term, which is renewable.

Stanton GersonStanton L. Gerson, MD - Case Comprehensive Cancer Center, Case Western Reserve University
Chair, External Advisory Committee

Stanton L. Gerson, MD, is the Director of the Case Comprehensive Cancer Center and the National Center for Regenerative Medicine at Case Western Reserve University, where he is the Asa and Patricia Shiverick–Jane B Shiverick (Tripp) Professor of Hematological Oncology and Case Western Reserve University Distinguished University Professor. He is a physician, Division of Hematology and Oncology, University Hospitals Cleveland Medical Center. Dr. Gerson has been active in the stem cell, hematologic malignancies, and developmental therapeutics programs.

John BuattiJohn Buatti, MD - Holden Comprehensive Cancer Center, University of Iowa

John Buatti, MD, is the Department Chair of Radiation Oncology at the University of Iowa and is a professor in Radiation Oncology, Otolaryngology and Neurosurgery. Dr. Buatti’s research is focused on using of imaging to improve outcomes for patients undergoing cancer therapy; radiation therapy in particular. Other areas of interest are in treating cancers of the Head and Neck and Brain, especially in the pediatric population.

Corey CasperCorey Casper, MD, MPH - Infectious Disease Research Institute (IDRI)

Corey Casper, MD, MPH, is the President and Chief Executive Officer at IDRI, a non-profit global health biotechnology organization whose mission is the eradication of infectious disease and cancer in low- and middle-income countries. Dr. Casper joined IDRI from the Fred Hutchinson Cancer Research Center and the University of Washington, where he remains a Professor of Medicine and Global Health. He brings extensive experience leading multi-phased international clinical trials in cancer and infectious disease from conception to publication to U.S. Food and Drug Administration (FDA) licensure.

David CellaDavid Cella, PhD - Robert H. Lurie Comprehensive Cancer Center, Northwestern University

David Cella, PhD, is Associate Director for Prevention and Control at Robert Lurie Comprehensive Cancer Center and Chair of the Department of Medical School Sciences, and Director, Institute for Public Health and Medicine – Center for Patient Centered Outcomes at Northwestern University. Dr. Cella’s career has focused on studying questions regarding quality of life measurement in clinical trials, cross-cultural equivalence of quality of life measurement, efficacy of psychosocial interventions in oncology, and medical outcomes research.

James DeGregoriJames DeGregori, PhD - University of Colorado, Anschutz Medical Campus

James DeGregori, PhD, is a Professor in the Department of Biochemistry and Molecular Genetics (faculty since 1997) and Deputy Director of the University of Colorado Cancer Center. He holds the Courtenay and Lucy Patten Davis Endowed Chair in Lung Cancer Research. His lab seeks to understand how aging and other carcinogenic conditions promote cancer evolution and to discover pathway dependencies in cancers that can be exploited therapeutically. His lab studies the evolution of cancer, in the context of their Adaptive Oncogenesis model, with a focus on how aging, smoking, Down Syndrome, and other insults influence cancer initiation and responses to therapy. The lab has developed this cancer model based on classic evolutionary principles, and substantiated this model by theoretical, experimental and computational studies.

Dexter FrederickDexter Frederick, MD - BEST Foundation

Dexter Frederick, MD, is the Founder and Executive Director of Brain Expansions Scholastic Training (BEST) Foundation. BEST helps minority students prepare confidently for careers in health care. By exposing middle school and high school students to different health care careers, the program aims to inspire them to pursue college degrees.

Lauren HackettLauren E. Hackett, MPA - Allen Institute 

Lauren E. Hackett, MPA, joined the Allen Institute in January 2019 and is responsible for leading operations, integrating strategy and planning efforts across the Institute. Hackett previously served as executive director for administration at Vanderbilt-Ingram Cancer Center and NYU Cancer Institute and held similar roles with the Yale School of Medicine and Yale Cancer Center and was the director of sponsored programs at Rockefeller University. Hackett has served on numerous cancer center and national advisory boards as well as peer review committees for the National Cancer Institute. She received her BA in Psychology at the University of Massachusetts and her MPA at the University of New Haven.

Kimberly KerstannKimberly F. Kerstann, PhD - Emory University

Kimberly F. Kerstann, PhD, serves as the Senior Director for Research Administration at Winship Cancer Institute of Emory University. She serves as a member of the Winship senior leadership team to ensure the coordination and implementation of transdisciplinary and collaborative research programs.


Karen KnudsenKaren E. Knudsen, MBA, PhD - Sidney Kimmel Cancer Center at Jefferson Health

Karen E. Knudsen, MBA, PhD, is the Executive Vice President of Oncology Services at Jefferson Health. A leading expert in the molecular basis of hormone-dependent cancer development and progression, She focuses her work on developing new means to prevent or treat lethal prostate cancers. Her studies that identify tumor suppressor and hormone receptor alterations have uncovered new targets for treating advanced disease, and have led to innovative, biomarker-driven clinical trials.

Elizabeth PlatzElizabeth Platz, MPH, ScD - Johns Hopkins Bloomberg School of Public Health and the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins

Elizabeth Platz, MPH, ScD, is Professor of Epidemiology in the Cancer Epidemiology Track at the Johns Hopkins Bloomberg School of Public Health and Co-Leader of the Cancer Prevention and Control Program at the SKCCC. With a research focus on the molecular and genetic epidemiology of prostate and colon cancers that incorporates health disparities and strives toward translation of findings, her expertise complements the full spectrum of Aims of the Cancer Epidemiology Program.

Charlie RudinCharlie Rudin, MD, PhD - Memorial Sloan Kettering Cancer Center

Charlie Rudin, MD, PhD, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials. He is Chief, Thoracic Oncology Service; Co-Director, Druckenmiller Center for Lung Cancer Research; and Sylvia Hassenfeld Chair in Lung Cancer Research at Memorial Sloan Kettering.

Peggie SherryPeggie Sherry - Faces of Courage Foundation

Peggie Sherry is CEO/Founder of Faces of Courage Foundation, Inc. This nonprofit 501 (c) 3 organization provides life enriching experiences to kids, women and families touched by cancer and/or blood disorders. Faces of Courage is the first organization in the U.S. to tailor a women’s weekend camp for minority cancer survivors and is considered a leader in minority outreach and education.

Yu ShyrYu Shyr, PhD - Vanderbilt Ingram Cancer Center

Yu Shyr, PhD - Harold L. Moses Chair in Cancer Research; Director, Vanderbilt Center for Quantitative Sciences; Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design (VANGARD); Associate Director for Quantitative Sciences Integration, VICC. Professor and Chair, Department of Biostatistics; and Professor of Biomedical Informatics and Health Policy. Dr. Shyr has developed biostatistical and bioinformatic methodologies for clinical trial design, high-dimensional data preprocessing, estimating relative potency in a parallel line bioassay, and other statistical and bioinformatic approaches.

Celette SkinnerCelette Sugg Skinner, PhD - UT Southwestern Simmons Cancer Center

Celette Sugg Skinner, PhD, is Professor and Chair of UT Southwestern’s Department of Clinical Sciences and holds the Parkland Community Medicine Professorship. She is the founding Associate Director for Population Sciences for the Harold C. Simmons Comprehensive Cancer Center. A pioneer in computer-tailored communications, Dr. Skinner has spent 30 years developing and testing innovative behavior-change interventions, working primarily among traditionally underserved groups. Her recent work focuses on multilevel interventions that meaningfully use electronic health records to identify patients in need of intervention, use clinically collected information to generate and deliver algorithm-driven tailored interventions, and track intervention outcomes.

Jenny TingJenny PY Ting, PhD - Lineberger Comprehensive Cancer Center, University of North Carolina

Jenny PY Ting, PhD, William R. Kenan, Jr. Distinguished Professor Genetics, Lineberger Cancer Center. Dr. Ting’s laboratory has broad interest in the application of cutting-edge ideas and technology to the study of disease-relevant issues. Major directions include innate immunity, dendritic cell function, cell death, autophagy, signal transduction, gene discovery, functional genomics and proteomics, nanoparticles, gene regulation, neuro-inflammation and microglial cells. Clinical issues of interest include multiple sclerosis, cancer, autoimmune diseases, biologic therapy, infection and inflammation.

Robert VonderheideRobert Vonderheide, MD, DPhil - John H Glick Abramson Cancer Center

Robert Vonderheide, MD, DPhil, is the Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center’s Director Professor in the Perelman School of Medicine. He is Vice Dean for Cancer Programs at PSOM and Vice President of Cancer Programs for the University of Pennsylvania Health System. He serves as Lead Physician for the Cancer Service Line of the Health System. The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer.

Robert WinnRobert Winn, MD - Virginia Commonwealth University, Massey Cancer Center

Robert Winn, MD, was appointed director of VCU Massey Cancer Center on December 2, 2019. His current basic science research, which has been supported by multiple National Institutes of Health awards, focuses on the cellular pathways that drive the development and progression of lung cancer and the role of cell division arrest in lung cancer. Winn is committed to community-engaged research centered on eliminating health disparities. He has received national and international acclaim for his efforts to empower underserved patient populations, improve health care delivery and ensure equal access to cancer care.